Pharmacological and Device-Based Intervention for Preventing Heart Failure After Acute Myocardial Infarction - A Clinical Review

Circ J. 2024 Oct 25;88(11):1727-1736. doi: 10.1253/circj.CJ-24-0633. Epub 2024 Sep 13.

Abstract

In patients with acute myocardial infarction (MI), heart failure (HF) is one of the most common complications that is associated with a significant burden of mortality and healthcare resources. The clinical benefits of key HF drugs, the so-called "4 pillars" or "fantastic 4", namely β-blockers, mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitor, and sodium-glucose cotransporter 2 inhibitors, have been established in patients with HF with reduced ejection fraction, whereas the effects of these drugs are not comprehensively appreciated in patients with acute MI. This review summarizes current evidence on pharmacological and device-based interventions for preventing HF after acute MI.

Keywords: Acute myocardial infarction; Heart failure; Medication.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin Receptor Antagonists / therapeutic use
  • Heart Failure* / therapy
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Myocardial Infarction* / complications
  • Myocardial Infarction* / therapy
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Substances

  • Mineralocorticoid Receptor Antagonists
  • Adrenergic beta-Antagonists
  • Sodium-Glucose Transporter 2 Inhibitors
  • Angiotensin Receptor Antagonists